This article is more than 5 years old. Information may no longer be current.

VIDEO: Improved physical function for patients with RA when switched from adalimumab to sarilumab

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Gerd R. Burmester, MD, spoke about the efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of the MONARCH trial.

Burmester said results showed that patients with rheumatoid arthritis had improved physical function when switched from adalimumab 40 mg monotherapy to sarilumab 200 mg every 2 weeks. Additionally, the researchers found the safety profile for this open-label extension trial was consistent with the safety profile found in the MONARCH trial.